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Abstract
A unique feature of both human herpesvirus 6A and B (HHV-6A and B) among human herpesviruses is their ability to
integrate into chromosomal telomeres. In some individuals integrated viral genomes are present in the germ-line and result
in the vertical transmission of HHV-6; however, little is known about the disease associations of germ-line transmitted,
chromosomally integrated HHV-6 (ciHHV-6). Recent publications suggest that HHV-6 is associated with classical Hodgkin
lymphoma (cHL). Here we examine the prevalence of ciHHV-6 in 936 cases of cHL and 563 controls by screening with a
duplex TaqMan assay and confirming with droplet digital PCR. ciHHV-6 was detected in 10/563 (1.8%) controls and in all but
one individual the virus was HHV-6B. Amongst cases 16/936 (1.7%) harboured ciHHV-6, thus demonstrating no association
between ciHHV-6 and risk of cHL.
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Introduction
Recent publications suggest an association between human
herpesvirus 6 (HHV-6) A and B and classical Hodgkin lymphoma
(cHL) [1,2]. cHL has a peak incidence in young adults (15–35
years) and epidemiological evidence suggests that an infectious
agent may be involved in the aetiology of these cases [3]. A third of
all cHL cases in industrialised countries are causally associated
with Epstein-Barr virus (EBV); however, these cases are relatively
more common in older adults and young children. It is therefore
plausible that another virus is involved in the pathogenesis of
EBV-negative cHL [3].
HHV-6A and -6B are two distinct but related human
herpesviruses [4]. A feature unique to HHV-6A and B among
human herpesviruses is their ability to integrate into the telomeres
of human chromosomes [5,6]. In a proportion of individuals the
integrated virus is present in every nucleated cell in the body and
passed to subsequent generations in a Mendelian fashion [7,8]; this
phenomenon is generally referred to as chromosomally integrated
HHV-6 (ciHHV-6). The reported prevalence of ciHHV-6 among
healthy individuals ranges from 0.8–4% [9].
Luppi et al. (1993) first described integrated HHV-6 genomes in
three patients with high viral loads in peripheral blood; one of
these patients had cHL and a second had a B-cell non-Hodgkin’s
lymphoma [10]. Strenger et al. (2013) also documented ciHHV-6
in a cHL case, raising the possibility of a specific association
between ciHHV-6 and cHL [2]. However, a recent study from
Hubacek et al. (2013) did not find a difference in ciHHV-6
prevalence in patients with malignant disease and healthy controls
[11]. Whilst this study did include 267 patients with cHL, it did
not explicitly look at the prevalence of ciHHV-6 among these
individuals. To conclusively determine whether ciHHV-6 is
associated with cHL, we screened 936 cases of cHL and 563
healthy controls for ciHHV-6 using a quantitative PCR assay, and
confirmed the presence of ciHHV-6 using droplet digital (ddPCR).
Materials and Methods
Subjects and Samples
Samples from 1508 subjects were analysed. These comprised:
375 cases and 349 controls from the Scotland and Newcastle
Epidemiological Study of Hodgkin’s disease (SNEHD) [12]; 70
cases and 40 controls from the Young Adult Haematological
malignancy and Hodgkin’s disease Case Control Study
(YHHCCS) [13]; 170 cases and 174 controls from the Epidemi-
ology and Genetics Lymphoma Case Control Study (ELCCS)
[14]; and 321 cases from a prospective collection of newly
diagnosed cHL cases in Scotland and the north of England.
Subject characteristics including sex, age, tumour EBV status and
histological subtype are summarised in Table 1. DNA was
extracted from peripheral blood samples using standard proce-
dures and subsequently whole genome amplified (WGA)
(KBioscience, Herts, UK).
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Ethics Statement
Ethical approval was obtained from research ethics committees
(REC) for each of the four contributing studies as follows:
SNEHD, NHS Research Ethics Committee for Wales, REC
reference number 08/MRE09/72; YHHCCS, NHS Greater
Glasgow and Clyde West of Scotland Research Ethics Committee
4, REC reference number 09/S0704/73; ELCCS, NHS England
Northern and Yorkshire Research Ethics Committee, REC
reference number MREC/97/3/33; local case series, NHS
Scotland Multi-Centre Research Ethics Committee for Scotland,
REC reference number 06MRE00/83. All subjects provided
written, informed consent.
Quantitative PCR Assays
All samples were analysed using a duplex TaqMan qPCR assay
that detects both the single copy b-GLOBIN gene and the U7
gene of HHV-6A and B; both components of the assay have been
described previously (Table 2) [15,16]. Each 25 ml reaction
contained 16TaqMan Universal PCR MasterMix without
UNG, b-GLOBIN primers at 50 nM and U7 primers at
150 nM, both probes at 200 nM (all Life Technologies, Paisley,
UK) and 50–100 ng of template DNA. Positive controls for the U7
and b-GLOBIN assays consisted of the HHV-6A U7 amplicon
region in pBlueScript (Dundee Cell Products, Dundee, UK) and
HHV-6-negative human genomic DNA, respectively. Samples
with known ciHHV-6 were also analysed in optimisation
experiments. A no template control was included after every two
samples. Amplification using default cycling parameters and
results analysis were performed on a 7500 Fast Real-Time PCR
system with Sequence Detection software v2.0.6 (Life Technolo-
gies). DCT values (CTU7– CTb-GLOBIN) were used to determine
whether a sample contained ciHHV-6. Where possible, cases
suspected of having ciHHV-6 were retested using the original
DNA sample, i.e. non-WGA DNA.
Samples containing ciHHV-6 were further analysed to deter-
mine whether the virus was HHV-6A or B using previously
described TaqMan qPCR assays detecting the POL gene of HHV-
6A and HHV-6B (Table 2) [17]. qPCR was performed as above
with the exception that primers were at 300 nM.
Droplet Digital PCR
ddPCR copy number variant (CNV) analysis was used to
confirm the presence of ciHHV-6 in positive samples identified in
the qPCR screen. Duplex ddPCR incorporating a commercially
available endogenous control assay (Human RPP30, Bio-Rad
Laboratories, Hertfordshire, UK) and either the HHV-6A or
HHV-6B POL, with the exception that probes were labelled with
the reporter dye HEX and the dark quencher BHQ1 (Table 2).
To ensure even partitioning of DNA molecules into droplets,
pre-digestion of the DNA is advised [18]. We utilised an ‘in-
reaction’ digestion method, as described below, to avoid excessive
manipulation of the sample before amplification.
ddPCRs were set up in duplicate in a 25 ml reaction volume.
Each consisted of: 16ddPCR Supermix for Probes without dUTP
(Bio-Rad Laboratories); 1.25 ml of a 206RPP30 primer/probe
mix; viral specific primers and probes at 300 nM and 200 nM,
respectively; 10–100 ng of template DNA and 1 ml of ‘digest mix’.
The ‘digest mix’ consisted of 5 U ml21 HindIII in 1x NEB buffer 2
(both New England BioLabs, Herts, UK). Twenty microlitres of
the reaction were loaded into DG8 cartridges along with 70 ml of
Droplet Generation Oil, and droplets were generated in a QX200
droplet generator (all Bio-Rad). The droplets were then transferred
into 96-well PCR reaction plates (Eppendorf, Stevenage, UK).
Thermal cycling was performed on a C1000 Touch Thermo
Cycler (Bio-Rad) using the following conditions: 95uC for
Table 2. Primers and probes used in screening assays, typing and ddPCR assays.
Name Sequence
(59-39)
B-GLOBIN
Forward Primer
GGCAACCCTAAGGTGAAGGC
B-GLOBIN
Reverse Primer
GGTGAGCCAGGCCATCACTA
B-GLOBIN Probe 6-FAM-ATGGCAAGAAAGTGCTCGGTGCCT-TAMRA
HHV-6 U7
Forward Primer
AAAATTTCTCACGCCGGTATTC
HHV-6 U7
Reverse Primer
CCTGCAGACCGTTCGTCAA
HHV-6 U7 Probe VIC-TCGGTCGACTGCCCGCTACCA-TAMRA
HHV-6A POL
Forward Primer
GGCCAGCCAGTCCTTTAGTAGA
HHV-6A POL
Reverse Primer
GGATGAGACTCATCGGTTTGTG
HHV-6A POL Probe 6-FAM-TCCCAAGCACAGACTCACGGATACAAGG-TAMRA*
HHV-6B POL
Forward Primer
GGCCAGCCAGTCCTTTAGTAGA
HHV-6B POL
Reverse Primer
GGATGAGACCCATCGGTTTGTG
HHV-6B POL Probe 6-FAM-TTCCAAGCACAGACTCGCGAACACAAGG-TAMRA*
*Reporter and quencher dyes were HEX and BHQ1, respectively for ddPCR.
doi:10.1371/journal.pone.0112642.t002
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10 minutes followed by 40 cycles of 94uC for 30 s and 60uC for
1 minute and a final extension at 98uC for 10 minutes. After
amplification, results were analysed on a QX200 Droplet Reader
using QuantaSoft analysis software v1.4.0. DNA samples extracted
from ciHHV-6-positive lymphoblastoid cell lines (LCLs) were used
as positive controls (kindly provided by Dr. D Clark, Royal Barts
NHS Trust, London).
Statistical Analysis
The proportion of individuals with ciHHV-6 in cases and
controls, and subgroups stratified by age group and sex (all
subjects), and histological subtype and EBV status (cases), were
compared and Pearson’s chi-squared test was used to test whether
differences were statistically significant. All statistical analyses were
implemented using SPSS v19.0 (IBM, Middlesex, UK).
Results
ciHHV-6 screen of cHL cases and controls
Cases with ciHHV-6 generally contain one HHV-6 genome per
diploid genome and therefore would be expected to contain a b-
GLOBIN to U7 copy number ratio of 2:1. Using non-WGA DNA
the components of the duplex TaqMan assay had similar
efficiencies; however, b-GLOBIN standard curves, generated
using ten-fold dilutions of PCR replicates, had a lower y-intercept
than the corresponding U7 standard curves resulting in a DCT of
approximately 3, rather than the expected DCT of 1. Using WGA
DNA, the U7 component of the duplex TaqMan assay was less
efficient than the b-GLOBIN component, and samples generally
had higher CT values in the b-GLOBIN assay, resulting in larger
and more variable DCT values All samples with a DCT#6 were
therefore considered likely to contain ciHHV-6. All samples had a
b-GLOBIN CT#32. Testing of replicates of WGA DNA from
confirmed ciHHV-6-positive samples confirmed that ciHHV-6
was consistently detected when a CT of 32 was observed in the b-
GLOBIN assay.
Following the initial screen, 26 subjects were identified as
potentially ciHHV-6-positive. The DCT values of the respective
samples ranged from 0.94–5.67. Non-WGA DNA was available
from 21 of these subjects and analysis of these samples gave DCT
values in the range 2.61–3.69, with the exception of one sample
(from subject 4298) which had a DCT of 0.97 consistent with the
presence of more than one integrated viral genome. Occasional
other samples gave rise to low-level HHV-6 positive results but, of
these, the lowest DCT in the duplex assay was 10.4; thus samples
with ciHHV-6 and exogenously acquired HHV-6 appeared clearly
separable.
HHV-6 typing was performed on all 26 samples with ciHHV-6;
two subjects were HHV-6A-positive and the remainder HHV-6B-
positive.
Confirmation of ciHHV-6 with ddPCR
To confirm the presence of ciHHV-6 in these samples we
conducted ddPCR on the 21 samples with available material.
ddPCR utilises reactions similar to TaqMan qPCR to quantify
target sequences with a very high degree of accuracy. The QX200
ddPCR system (BioRad) partitions a 20 ml reaction volume into up
to 20,000 droplets. PCR amplification occurs in each droplet and
effectively increases the efficiency of the reaction by reducing
competition between targets and confining the reaction compo-
nents to a finite area. Each droplet acts as a single replicate and as
the droplet volume is known this allows the absolute concentration
of DNA target molecules to be calculated [18]. Recently ddPCR
has been used as a means of detecting ciHHV-6 [19,20]. We
developed two duplex ddPCR assays that target the human
RPP30 gene and either the HHV-6A POL or HHV-6B POL
gene; subjects were typed for HHV-6A and B, and the appropriate
assay was used on each sample.
The current gold standard for confirming ciHHV-6 is
fluorescent in situ hybridisation (FISH); we therefore used DNA
from LCLs, which had been confirmed to be ciHHV-6-positive by
FISH, as positive controls. Both the HHV-6A and HHV-6B
ddPCR duplex assays showed good separation of positive and
negative droplets when run on ciHHV-6-positive LCL DNA
(Fig. 1). The average number of HHV-6 genome copies per cell
(gc/cell) was 1.07 and 1.01 for LCLs 7-17p13.3 (HHV-6A) and 4-
11p14.5 (HHV-6A), respectively (Fig. 2). The appropriate duplex
assay was conducted in duplicate on samples identified in the
initial screen, with the exception of samples from 3572 and 3757
where DNA was limited. We analysed approximately 14,000
droplets per reaction. In all but one case the average HHV-6 copy
number clustered around 1 gc/cell (range 0.884–1.2 gc/cell)
(Fig. 2). The sample from subject 4298 had a HHV-6 copy
number of 4.05 gc/cell (Poisson 95% confidence interval: 3.96,
4.14). ddPCR was repeated on this sample using a duplex assay
which amplifies RPP30 and the HHV-6 U7 gene; the observed
HHV-6 copy number was 3.95 gc/cell (Poisson 95% confidence
interval: 3.69, 4.22). There was no evidence of off-target
amplification, consistent with all these genomes being HHV-6A.
These data suggest that subject 4298 has four integrated copies of
HHV-6A per cell.
ciHHV-6 prevalence in cHL cases and controls
Of the 26 ciHHV-6-positive subjects identified, 16 (1.7%) were
cases and 10 (1.8%) controls; therefore, there was no statistically
significant difference between cases and controls (p=0.92). When
cases and controls were broken down by study (Table 3 and Table
S1) there was no evidence of heterogeneity. Of the two subjects
with HHV-6A, one was a case and the other a control.
The prevalence of ciHHV-6 was analysed by sex and age in four
age groups: 0–14, 15–34, 35–49 and $50 years. No statistically
significant differences were observed (data not shown). Cases were
further analysed with respect to EBV status of tumours,
histological subtype (nodular sclerosis versus mixed cellularity),
and age in two groups (15–34 years and $50 years, to reflect the
bimodal age distribution of cHL), or sex. No differences in
prevalence were observed by EBV tumour status, histological
subtype and sex. Older adult cases (7/236, 2.97%) were more
likely to have ciHHV-6 than younger adult cases (5/484, 1.03%)
and this difference approached statistical significance (p=0.057).
The difference between these two age groups among controls (4/
223, 1.79% and 4/191, 2.09%, respectively) was not significant
(p=0.83).
Discussion
This is the largest study, to date, to investigate the prevalence of
ciHHV-6 among cHL patients, and also one of the largest screens
for ciHHV-6 in control subjects in the UK. We identified 26
subjects including 16 (1.7%) cHL cases and 10 (1.8%) controls
with ciHHV-6. There was no difference in the prevalence of
ciHHV-6 in cHL cases and controls, suggesting that inheritance of
an integrated HHV-6 genome does not increase risk of this
disease. The prevalence of ciHHV-6 among control subjects
reported here is within the range previously reported for Western
populations and the proportion of positive subjects is not
significantly different from other studies of controls with sample
size $100 [9,11,21–24].
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Further analysis of cases did not reveal any association between
prevalence of ciHHV-6 and EBV status or histological subtype of
cHL. When cases were stratified by age group, older adult cases
were found to be more frequently ciHHV-6-positive than younger
adult cases and these differences approached statistical significance
(p=0.057). Given the small number of ciHHV-6-positive samples
and lack of case control differences, this is likely to be due to
chance; however, since HHV-6 integrates into telomeres and
telomeres are involved in cell senescence [25], it remains possible
that this is biologically relevant and therefore this should be
addressed in future studies.
Figure 1. Analysis of ciHHV-6 by droplet digital PCR. One dimensional ddPCR plots for positive controls 7-17p13.3 (HHV-6A, panels A & B) and
4-11p14.5 (HHV-6B, panels C & D). Each control has two plots one representing the RPP30 FAM (blue) channel (panels A & C) and the other the HHV-6
HEX (green) channel (panels B & D). Each point represents a single droplet, which is scored as positive (coloured) or negative (grey) depending on the
fluorescent amplitude.
doi:10.1371/journal.pone.0112642.g001
Figure 2. HHV-6 copies per cell in individuals identified as ciHHV-6-positive. Estimated HHV-6 genome copies per cell in subjects
suspected to have ciHHV-6 and in positive controls (7-17p13.3 and 4-11p14.5). HHV-6A subjects are plotted in red and HHV-6B subjects in green. Error
bars indicate the Poisson 95% confidence interval for each point.
doi:10.1371/journal.pone.0112642.g002
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The results confirm that ddPCR is more precise than
conventional TaqMan PCR for detecting the presence of
ciHHV-6 in DNA samples. The HHV-6 genome copy number
estimates clustered around values which suggest inherited
genomes. We observed a copy number range of 0.884–1.2 gc/
cell in all individuals except subject 4298, and in most cases the
average value was extremely close to 1 with 95% confidence
intervals approaching or crossing 1. Failure to detect a copy
number of exactly 1 may relate to the age of the samples as recent
reports in the literature suggest that sample age can affect CNV
analysis results [26]. The ciHHV-6-positive samples analysed in
this study were collected between 1992 and 2009 and therefore
sample DNA was between 5 and 22 years old. However, it cannot
be ruled out that subjects with a HHV-6 copy number .1 gc/cell
have some degree of active infection, and that subjects with a
HHV-6 copy number,1 gc/cell have some cells that have deleted
all or part of their viral genomes, as has been described recently
[23].
We identified and report for the first time an individual who is
likely to have four integrated copies of HHV-6A. There has been a
reported case of ciHHV-6 with two integrated viruses; in this case
it was confirmed that a single copy HHV-6 genome had been
inherited from each parent [8]. It is possible that this individual
has inherited two integrated viruses from each parent; however,
other possibilities such as new primary integration events,
reactivation and further integration of already present virus or
integration of viral genome concatemers cannot be excluded.
Exogenously acquired HHV-6A appears to have a low
prevalence in industrialised countries. In the USA, 97–100% of
all symptomatic and asymptomatic primary infections in infants
are HHV-6B [27–29]. This is mirrored in European populations
where up to 95% of primary infections are HHV-6B [30,31]. In
contrast, in Sub-Saharan Africa, HHV-6A is the dominant virus
accounting for 86% of asymptomatic infections in Zambian infants
[32]. It has been suggested previously that between one-fifth and
one-third of ciHHV-6 genomes are HHV-6A [33]. Given that
most of the contributing studies analysed individuals from
industrialised countries, this in turn leads to the suggestion that
HHV-6A may integrate more frequently than HHV-6B. In studies
with ten or more ciHHV-6-positive subjects HHV-6A has
accounted for 6.8–40% of ciHHV-6 genomes [22,23,34]. In the
present study we identified only 2 subjects (8%) with ciHHV-6A.
These data are more consistent with the idea that the proportion
of HHV-6A among ciHHV-6-positive subjects reflects the
proportions of HHV-6A and HHV-6B in the underlying
population. Both ciHHV-6A subjects identified in this study are
white British.
In conclusion, the data presented here suggest that the
prevalence of ciHHV-6 in the UK is ,1.8% but do not support
an association between ciHHV-6 and cHL risk.
Supporting Information
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this study.
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